Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications: A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group

Akihito Shinohara, Kumi Oshima, Shigeo Fuji, Katsutsugu Umeda, Shinichi Kako, Mineo Kurokawa, Nobuhiro Tsukada, Masanobu Kasai, Takakazu Kondo, Yoshiko Hashii, Hirohisa Nakamae, Kazuhiro Ikegame, Yoshiyuki Kosaka, Akira Shimada, Yuichiro Nawa, Yoshimitsu Makoto, Atsuta Yoshiko, Takahiro Fukuda, Junji Tanaka, Masao Ogata

Research output: Contribution to journalArticle

Abstract

Little is known about stem cell transplantation in solid organ transplantation (SOT) recipients. We conducted a nationwide retrospective survey of Japan Society for Hematopoietic Stem Cell Transplantation centers. A total of 19 patients who underwent 22 hematopoietic stem cell transplantations (HSCTs) after SOT were identified: 5 autologous HSCTs and 17 allogeneic HSCTs were performed. Patients who underwent autologous HSCT received a liver (n = 4) or kidney (n = 1) transplant. All 5 patients achieved neutrophil engraftment, and 2 of 3 patients with hepatoblastoma were alive at 1 year after HSCT. Allogeneic HSCT was performed in 16 patients (7 liver transplant recipients and 9 kidney transplant recipients). Among these, 2 donors were identical for both transplantations. All but 1 patient achieved neutrophil engraftment. The 5-year overall survival rate was 41.7%, but that in patients with malignant disease (n = 13) was much lower than the overall rate (23.1%). Only 1 patient with malignant disease underwent allogeneic HSCT in nonremission. In allogeneic HSCT after kidney transplantation, post-transplantation (1 year) kidney function in 5 evaluable patients was significantly lower than that before allogeneic HSCT, and 3 patients experienced renal rejection. However, no severe hepatic rejection was noted. In SOT recipients, HSCT is a potentially curable treatment for hematologic disorders, but it must be performed with caution, especially in patients with malignancy.

Original languageEnglish
JournalBiology of Blood and Marrow Transplantation
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Hematopoietic Stem Cell Transplantation
Japan
Transplants
Organ Transplantation
Kidney
Liver
Neutrophils
Surveys and Questionnaires
Transplantation
Hepatoblastoma
Stem Cell Transplantation
Kidney Transplantation
Survival Rate
Tissue Donors

Keywords

  • Hematopoietic stem cell transplantation
  • Liver failure
  • Renal failure
  • Solid organ transplantation
  • Transplantation-related complications

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications : A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group. / Shinohara, Akihito; Oshima, Kumi; Fuji, Shigeo; Umeda, Katsutsugu; Kako, Shinichi; Kurokawa, Mineo; Tsukada, Nobuhiro; Kasai, Masanobu; Kondo, Takakazu; Hashii, Yoshiko; Nakamae, Hirohisa; Ikegame, Kazuhiro; Kosaka, Yoshiyuki; Shimada, Akira; Nawa, Yuichiro; Makoto, Yoshimitsu; Yoshiko, Atsuta; Fukuda, Takahiro; Tanaka, Junji; Ogata, Masao.

In: Biology of Blood and Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Shinohara, Akihito ; Oshima, Kumi ; Fuji, Shigeo ; Umeda, Katsutsugu ; Kako, Shinichi ; Kurokawa, Mineo ; Tsukada, Nobuhiro ; Kasai, Masanobu ; Kondo, Takakazu ; Hashii, Yoshiko ; Nakamae, Hirohisa ; Ikegame, Kazuhiro ; Kosaka, Yoshiyuki ; Shimada, Akira ; Nawa, Yuichiro ; Makoto, Yoshimitsu ; Yoshiko, Atsuta ; Fukuda, Takahiro ; Tanaka, Junji ; Ogata, Masao. / Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications : A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group. In: Biology of Blood and Marrow Transplantation. 2019.
@article{8a37cd72344d401bb98e51894bfc68e9,
title = "Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications: A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group",
abstract = "Little is known about stem cell transplantation in solid organ transplantation (SOT) recipients. We conducted a nationwide retrospective survey of Japan Society for Hematopoietic Stem Cell Transplantation centers. A total of 19 patients who underwent 22 hematopoietic stem cell transplantations (HSCTs) after SOT were identified: 5 autologous HSCTs and 17 allogeneic HSCTs were performed. Patients who underwent autologous HSCT received a liver (n = 4) or kidney (n = 1) transplant. All 5 patients achieved neutrophil engraftment, and 2 of 3 patients with hepatoblastoma were alive at 1 year after HSCT. Allogeneic HSCT was performed in 16 patients (7 liver transplant recipients and 9 kidney transplant recipients). Among these, 2 donors were identical for both transplantations. All but 1 patient achieved neutrophil engraftment. The 5-year overall survival rate was 41.7{\%}, but that in patients with malignant disease (n = 13) was much lower than the overall rate (23.1{\%}). Only 1 patient with malignant disease underwent allogeneic HSCT in nonremission. In allogeneic HSCT after kidney transplantation, post-transplantation (1 year) kidney function in 5 evaluable patients was significantly lower than that before allogeneic HSCT, and 3 patients experienced renal rejection. However, no severe hepatic rejection was noted. In SOT recipients, HSCT is a potentially curable treatment for hematologic disorders, but it must be performed with caution, especially in patients with malignancy.",
keywords = "Hematopoietic stem cell transplantation, Liver failure, Renal failure, Solid organ transplantation, Transplantation-related complications",
author = "Akihito Shinohara and Kumi Oshima and Shigeo Fuji and Katsutsugu Umeda and Shinichi Kako and Mineo Kurokawa and Nobuhiro Tsukada and Masanobu Kasai and Takakazu Kondo and Yoshiko Hashii and Hirohisa Nakamae and Kazuhiro Ikegame and Yoshiyuki Kosaka and Akira Shimada and Yuichiro Nawa and Yoshimitsu Makoto and Atsuta Yoshiko and Takahiro Fukuda and Junji Tanaka and Masao Ogata",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2019.08.021",
language = "English",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications

T2 - A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group

AU - Shinohara, Akihito

AU - Oshima, Kumi

AU - Fuji, Shigeo

AU - Umeda, Katsutsugu

AU - Kako, Shinichi

AU - Kurokawa, Mineo

AU - Tsukada, Nobuhiro

AU - Kasai, Masanobu

AU - Kondo, Takakazu

AU - Hashii, Yoshiko

AU - Nakamae, Hirohisa

AU - Ikegame, Kazuhiro

AU - Kosaka, Yoshiyuki

AU - Shimada, Akira

AU - Nawa, Yuichiro

AU - Makoto, Yoshimitsu

AU - Yoshiko, Atsuta

AU - Fukuda, Takahiro

AU - Tanaka, Junji

AU - Ogata, Masao

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Little is known about stem cell transplantation in solid organ transplantation (SOT) recipients. We conducted a nationwide retrospective survey of Japan Society for Hematopoietic Stem Cell Transplantation centers. A total of 19 patients who underwent 22 hematopoietic stem cell transplantations (HSCTs) after SOT were identified: 5 autologous HSCTs and 17 allogeneic HSCTs were performed. Patients who underwent autologous HSCT received a liver (n = 4) or kidney (n = 1) transplant. All 5 patients achieved neutrophil engraftment, and 2 of 3 patients with hepatoblastoma were alive at 1 year after HSCT. Allogeneic HSCT was performed in 16 patients (7 liver transplant recipients and 9 kidney transplant recipients). Among these, 2 donors were identical for both transplantations. All but 1 patient achieved neutrophil engraftment. The 5-year overall survival rate was 41.7%, but that in patients with malignant disease (n = 13) was much lower than the overall rate (23.1%). Only 1 patient with malignant disease underwent allogeneic HSCT in nonremission. In allogeneic HSCT after kidney transplantation, post-transplantation (1 year) kidney function in 5 evaluable patients was significantly lower than that before allogeneic HSCT, and 3 patients experienced renal rejection. However, no severe hepatic rejection was noted. In SOT recipients, HSCT is a potentially curable treatment for hematologic disorders, but it must be performed with caution, especially in patients with malignancy.

AB - Little is known about stem cell transplantation in solid organ transplantation (SOT) recipients. We conducted a nationwide retrospective survey of Japan Society for Hematopoietic Stem Cell Transplantation centers. A total of 19 patients who underwent 22 hematopoietic stem cell transplantations (HSCTs) after SOT were identified: 5 autologous HSCTs and 17 allogeneic HSCTs were performed. Patients who underwent autologous HSCT received a liver (n = 4) or kidney (n = 1) transplant. All 5 patients achieved neutrophil engraftment, and 2 of 3 patients with hepatoblastoma were alive at 1 year after HSCT. Allogeneic HSCT was performed in 16 patients (7 liver transplant recipients and 9 kidney transplant recipients). Among these, 2 donors were identical for both transplantations. All but 1 patient achieved neutrophil engraftment. The 5-year overall survival rate was 41.7%, but that in patients with malignant disease (n = 13) was much lower than the overall rate (23.1%). Only 1 patient with malignant disease underwent allogeneic HSCT in nonremission. In allogeneic HSCT after kidney transplantation, post-transplantation (1 year) kidney function in 5 evaluable patients was significantly lower than that before allogeneic HSCT, and 3 patients experienced renal rejection. However, no severe hepatic rejection was noted. In SOT recipients, HSCT is a potentially curable treatment for hematologic disorders, but it must be performed with caution, especially in patients with malignancy.

KW - Hematopoietic stem cell transplantation

KW - Liver failure

KW - Renal failure

KW - Solid organ transplantation

KW - Transplantation-related complications

UR - http://www.scopus.com/inward/record.url?scp=85073074361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073074361&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2019.08.021

DO - 10.1016/j.bbmt.2019.08.021

M3 - Article

C2 - 31494230

AN - SCOPUS:85073074361

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -